X-Chem and Kymera expand partnership to 12 targets
X-Chem and Kymera Therapeutics have expanded their collaboration, which will now comprise 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration. With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera – using its… Read More